165668-23-5

Basic information

• Product Name: N-(7-indolyl)-4-nitrobenzenesulfonamide
• Synonyms: N-(7-indolyl)-4-nitrobenzenesulfonamide
• CAS NO: 165668-23-5
• Molecular Weight: 317.325
• Mol File: 165668-23-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(7-indolyl)-4-nitrobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(7-indolyl)-4-nitrobenzenesulfonamide(165668-23-5)
• EPA Substance Registry System: N-(7-indolyl)-4-nitrobenzenesulfonamide(165668-23-5)

Safety Data

• Hazardous Substances Data: 165668-23-5(Hazardous Substances Data)

Upstream product

• 292853-66-8 2-(2-(2-nitrophenyl)hydrazono)propionic acid ethyl ester 
• 6960-45-8 7-nitro-1H-indole-2-carboxylic acid 
• 6960-46-9 ethyl 7-nitroindole-2-carboxylate 
• 6960-42-5 7-nitro-1H-indole 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 81524-76-7 7-azido-1H-indole 
• 577-19-5 2-nitrophenyl bromide 
• 51417-51-7 7-bromo-1H-indole 
• 5192-04-1 7-aminoindole 

Downstream Products

• 1334245-99-6 N-(5,8-dimethyl-9H-carbazol-1-yl)-4-nitrobenzenesulfonamide 
• 1334246-00-2 4-amino-N-(5,8-dimethyl-9H-carbazol-1-yl)benzenesulfonamide 
• 165668-25-7 4-Amino-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide 
• 165668-24-6 N-(3-chloro-7-indolyl)-4-nitrobenzenesulfonamide 

Relevant articles and documents

Benzenesulfonamide derivatives and pharmaceutical composition thereof

The present invention is related to derivatives of benzenesulfonamide represented by formula (I), and the pharmaceutical composition thereof. In addition, the benzenesulfonamide derivatives disclosed in the present invention can serve as potential cell cycle inhibitors, and thereby these benzenesulfonamide derivatives and the pharmaceutical composition thereof can be antitumor drug candidates, which might aim at cell cycle. Particularly, the benzenesulfonamide derivatives disclosed in the present invention may function as antitumor drugs to treat solid cancers.

Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle

Described herein is the discovery of a novel series of antitumor sulfonamides targeting G1 phase of the cell cycle. Cell cycle control in G1 phase has attracted considerable attention in recent cancer research, because many of the important proteins invol